Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Profit After Tax (2023 - 2026)

Contineum Therapeutics' Profit After Tax history spans 4 years, with the latest figure at -$14.5 million for Q1 2026.

  • Quarterly Profit After Tax rose 9.38% to -$14.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$58.5 million through Mar 2026, down 17.41% year-over-year, with the annual reading at -$60.0 million for FY2025, 41.93% down from the prior year.
  • Profit After Tax came in at -$14.5 million for Q1 2026, up from -$15.2 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $41.6 million in Q2 2023 to a low of -$16.0 million in Q2 2025.
  • The 4-year median for Profit After Tax is -$10.3 million (2024), against an average of -$7.2 million.
  • Year-over-year, Profit After Tax tumbled 121.68% in 2024 and then grew 9.38% in 2026.
  • Contineum Therapeutics' Profit After Tax stood at -$7.8 million in 2023, then crashed by 87.48% to -$14.6 million in 2024, then decreased by 4.21% to -$15.2 million in 2025, then grew by 4.47% to -$14.5 million in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Profit After Tax are -$14.5 million (Q1 2026), -$15.2 million (Q4 2025), and -$12.8 million (Q3 2025).